Psychiatr. pro Praxi, 2003; 2: 62-65
Antipsychotika druhé generace v léčbě akutní psychotické agitovanosti
- MUDr. Pavel Mohr Ph.D1,2
- 1
Psychiatrické centrum Praha, 3. LF UK, Praha
- 2
Centrum neurofarmakologických studií, 3. LF UK Praha
Keywords: agitation, schizophrenia, second generation antipsychotics, olanzapine, ziprasidone.
Published: December 31, 2003 Show citation
Mohr P. Antipsychotika druhé generace v léčbě akutní psychotické agitovanosti. Psychiatr. praxi. 2003;4(2):62-65.
Celá řada psychotických onemocnění, včetně schizofrenie, může být doprovázena akutním neklidem, agitovaností nebo agresivitou. Vedle farmakoterapie akutní agitovanosti nesmíme zapomínat ani na možnosti nefarmakologické intervence. Z psychofarmak vhodných k parenterální aplikaci se dosud nejčastěji používala zejména klasická antipsychotika a benzodiazepiny. Nověji máme k dispozici injekční formy některých antipsychotik druhé generace, olanzapinu a ziprasidonu. Oba tyto léky prokázaly svoji účinnost a snášenlivost ve dvojitě slepých studiích při intramuskulárním podání akutně agitovaným psychotickým nemocným. Ve srovnání s klasickými antipsychotiky prokazují injekční formy nových antipsychotik rychlejší nástup účinku a celkově příznivější profil vedlejších nežádoucích účinků. Mohou se tak stát léky první volby v terapii akutní psychotické agitovanosti.
SECOND GENERATION ANTIPSYCHOTICS IN TREATMENT OF ACUTE PSYCHOTIC AGITATION
Various psychotic disorders, including schizophrenia, may be associated with symptoms of acute agitation, or even aggression. In the pharmacotherapy of acute agitation, we can use so called rapid tranquilization. Besides drug treatment, non-pharmacological interventions, environmental and behavioral, are important part of the complex approach. The most extensively used psychotropic drugs are parenteral formulas of conventional antipsychotics and benzodiazepines. More recently, injection forms of some second generation antipsychotics, olanzapine and ziprasidone, have become available. Both drugs have shown their efficacy and tolerability in several double-blind trials of intramuscular administration in acutely agitated psychotic patients. Comparing to the conventional medication, injection forms of the novel antipsychotics have a faster onset of action and overall more favorable profile of side effects. Thus, they should become a first-line choice in the treatment of acute psychotic agitation.
Psychiatrické centrum Praha, III. lékařská fakulta Univerzity Karlovy v Praze,
Centrum neuropsychiatrických studií
Download citation
References
- Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441-448.
Go to original source...
Go to PubMed...
- Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61: 933-941.
Go to original source...
Go to PubMed...
- Citrome L. Atypical antipsychotics for acute agitation. Postgrad Med 2002; 112: 85-96.
Go to original source...
Go to PubMed...
- Citrome L. Current treatments of agitation and aggression. Medscape Portals Inc., 2002.
- Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001; 155: 128-134.
Go to original source...
Go to PubMed...
- Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999; 156: 142-144.
Go to original source...
Go to PubMed...
- Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry 2000; 61: 909-911.
Go to original source...
Go to PubMed...
- Karagianis JL, Dawe IC, Thakur A, Bégin S, Raskin J, Roychowdhurry SM. Rapid tranquilization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001; 62 (Suppl. 2): 12-16.
- Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62: 12-18.
Go to original source...
Go to PubMed...
- Libiger J, Švestka J, Seifertová D. Farmakoterapeutické postupy v léčbě schizofrenní poruchy. Praha: Academia Medica Pragensis 2002; 40 s.
- Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21: 389-397.
Go to original source...
Go to PubMed...
- Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Feldman PD, Mintzer JE, Beckett LM, Breier A. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494-504.
Go to original source...
Go to PubMed...
- Tardiff K. Assessment and management of violent patients, 2nd Ed. Washington - London: American Psychiatric Press 1996, 166 s.
- Volavka J. Neurobiology of violence. Washington - London: American Psychiatric Press 1995, 397 s.
- Wyant M, Diamond BI, O'Neal E, Sloan A, Borison RL. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 1990; 26: 126-129.
Go to PubMed...
- Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149-1151.
Go to original source...
Go to PubMed...